Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 3 | 2017
With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta have evolved in the year since its launch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profilesbut, on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.
What you will learn in this content:
- What is U.S. neurologists’ awareness of and familiarity with Zinbryta, and what are their perceptions of the product?
- To which patients are Zinbryta prescribers prescribing the drug, what are their reasons for prescribing it, and how satisfied are they with it?
- What are the promotional messages and activities that Biogen and AbbVie are using to support the Zinbryta launch?
- How do prescribers and nonprescribers compare across key metrics?
- How are the trial and adoption of Zinbryta tracking compared with other product launches in the MS market?
Methodology: ~75-100 U.S. neurologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten of these specialists participated in a 30-minute follow-up qualitative interview.
Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons
Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech
Related reports: Emerging Therapies: Ocrevus (Relapsing MS and PP-MS companion series), Emerging Therapies: Lemtrada
